CANF
Can-fite Biopharma·AMEX
--
--(--)
--
--(--)
1.69 / 10
Underperform
Fundamental analysis reveals Can-Fite BioPharma's core metrics are weak: Total operating revenue and Operating revenue both show -36.08% YoY decline, while Days sales outstanding at 338.23 days points to slow receivable collection. Only the Interest coverage ratio of 27.58 offers marginal strength. Historical back-tests associate these factors with negative monthly returns, underscoring the poor fundamental stance.
Analysis Checks(1/4)
Total operating revenue (YoY growth rate %)
Value-36.08
Score1/3
Weight19.18%
1M Return-0.79%
Value-36.08
Score1/3
Weight19.18%
1M Return-0.79%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight26.21%
1M Return-1.11%
Value27.58
Score2/3
Weight26.21%
1M Return-1.11%
Days sales outstanding
Value338.23
Score1/3
Weight36.12%
1M Return-1.57%
Value338.23
Score1/3
Weight36.12%
1M Return-1.57%
Operating revenue (YoY growth rate %)
Value-36.08
Score1/3
Weight18.49%
1M Return-0.76%
Value-36.08
Score1/3
Weight18.49%
1M Return-0.76%
Total operating revenue (YoY growth rate %)
Value-36.08
Score1/3
Weight19.18%
1M Return-0.79%
Value-36.08
Score1/3
Weight19.18%
1M Return-0.79%
Days sales outstanding
Value338.23
Score1/3
Weight36.12%
1M Return-1.57%
Value338.23
Score1/3
Weight36.12%
1M Return-1.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight26.21%
1M Return-1.11%
Value27.58
Score2/3
Weight26.21%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-36.08
Score1/3
Weight18.49%
1M Return-0.76%
Value-36.08
Score1/3
Weight18.49%
1M Return-0.76%
Is CANF fundamentally strong?
- CANF scores 1.69/10 on fundamentals and holds a Premium valuation at present. Backed by its -101.37% ROE, -1571.25% net margin, -0.62 P/E ratio, 1.30 P/B ratio, and 100.00% earnings growth, these metrics solidify its Underperform investment rating.
